Genomic Evolution of Breast Cancer Metastasis and Relapse

Lucy Yates(Guy's Hospital), Stian Knappskog(Haukeland University Hospital), David C. Wedge(Wellcome Sanger Institute), James H. R. Farmery(University of Cambridge), Santiago González(European Bioinformatics Institute), Iñigo Martincorena(Wellcome Sanger Institute), Ludmil B. Alexandrov(Los Alamos National Laboratory), Peter Van Loo(The Francis Crick Institute), Hans Kristian Haugland(Haukeland University Hospital), Peer Kaare Lilleng(Haukeland University Hospital), Gunes Gundem(Memorial Sloan Kettering Cancer Center), Moritz Gerstung(European Bioinformatics Institute), Elli Pappaemmanuil(Memorial Sloan Kettering Cancer Center), Patrycja Gazińska(King's College London), Shriram G. Bhosle(Wellcome Sanger Institute), David Jones(Wellcome Sanger Institute), Keiran Raine(Wellcome Sanger Institute), Laura Mudie(Wellcome Sanger Institute), Calli Latimer(Wellcome Sanger Institute), Elinor J. Sawyer(Guy's Hospital), Christine Desmedt(Université Libre de Bruxelles), Christos Sotiriou(Université Libre de Bruxelles), Michael R. Stratton(Wellcome Sanger Institute), Anieta M. Sieuwerts(Erasmus MC), Andy G. Lynch(University of Cambridge), John W.M. Martens(Erasmus MC), Andrea L. Richardson(Brigham and Women's Hospital), Andrew Tutt(Institute of Cancer Research), Per Eystein Lønning(Haukeland University Hospital), Peter J. Campbell(Wellcome Sanger Institute)
Cancer Cell
August 1, 2017
Cited by 690Open Access
Full Text

Abstract

Patterns of genomic evolution between primary and metastatic breast cancer have not been studied in large numbers, despite patients with metastatic breast cancer having dismal survival. We sequenced whole genomes or a panel of 365 genes on 299 samples from 170 patients with locally relapsed or metastatic breast cancer. Several lines of analysis indicate that clones seeding metastasis or relapse disseminate late from primary tumors, but continue to acquire mutations, mostly accessing the same mutational processes active in the primary tumor. Most distant metastases acquired driver mutations not seen in the primary tumor, drawing from a wider repertoire of cancer genes than early drivers. These include a number of clinically actionable alterations and mutations inactivating SWI-SNF and JAK2-STAT3 pathways.


Related Papers

No related papers found

Powered by citation graph analysis